Home › NDC Lookup › Ingredients › Triamcinolone Acetonide › 00713-0226-15
Triamcinolone Acetonide .25 mg/g Cream — NDC 00713-0226-15 package photo
Label image from the product's FDA listing (DailyMed) — may show a different pack size or an older label revision.

Triamcinolone Acetonide .25 mg/g Cream — NDC 0713-0226-15 (Billing 00713-0226-15)

by Cosette Pharmaceuticals, Inc. · 1 TUBE in 1 CARTON / 15 g in 1 TUBE

This is a package of Triamcinolone Acetonide .25 mg/g Cream from Cosette Pharmaceuticals, Inc., no longer marketed (first marketed Apr 2015), no longer in the FDA NDC Directory; retail pharmacies pay about $0.1198 per g (NADAC). It is the main listing for this product, which comes in 2 package sizes.

NDC 00713-0226-15
🏷️ FDA NDC (as labeled) 0713-0226-15 billing pads the labeler segment with a zero
This package
Contains15 g in 1 tube Cost per g$0.1198 NADAC Per package$1.80 / 15 g Pack sizes2 compare ↓
Also priced by: Medicaid pays $0.3580/unit · Part D plans $0.1230/unit — full pricing hub ↓
Main listing for product 0713-0226 · Also comes in: 80 g 0713-0226-80
Rx only Generic Discontinued Non-controlled ⚠ Discontinued by firm ⇄ Compare with another NDC
🗂️ FDA directory synced Oct 1, 2026 · this listing last changed Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

This page is curated, coded, and maintained by

Compiled from public FDA, CMS, DailyMed, NADAC, and related drug data sources. Editorial policy

NDC database record

One package, one record: these facts belong to NDC 0713-0226-15 alone.

Record
FDA NDC Directory package listing · Human prescription drug
Code segments
0713 labeler · 0226 product · 15 package
Package marketed since
Apr 14, 2015
Sample package
No — commercial package
Listing certified through
Dec 31, 2026
Barcode (UPC-A, from the NDC)
3 0713022615 8
Medicaid fills, this package
22,707 prescriptions in the last four reported quarters
FDA record last changed
Jul 24, 2026
⚠️
Other active recalls for Triamcinolone Acetonide (different manufacturers) — 1 · tap to view
These affect other manufacturers’ products for the same ingredient — not necessarily the exact NDC on this page.
Class II · Sep 28, 2023 — Presence of Particulate Matter: A product complaint of a piece of glass was identified in a vial. The piece of glass appears to be roughly 1 cm x 0.5 cm inside the vial. (Eugia US LLC) · FDA recall D-0041-2024
Each entry is an official FDA enforcement report — look up any recall number in the FDA recall database ↗
⚠️
Excluded from the active FDA NDC Directory. The labeler reported this product as discontinued, so it is excluded from the active NDC Directory. The listing was last certified through Oct 2015. A label may still appear on DailyMed, but the NDC is no longer in the current FDA NDC Directory. Search the FDA NDC Directory ↗

Identity & classification

Regulatory identifiers FDA, NLM and CMS codes for this package

FDA NDC (as labeled) 0713-0226-15
Product NDC 0713-0226
11-digit billing NDC 00713022615
NCPDP billing unit GM — per gram (weight)
RxCUI 1014314, 1085644
UNII F446C597KA
Application # ANDA089797
SPL Set ID 5b3bcc75-608d-23fd-91a5-0806d5fe32f5
Established class (EPC) Corticosteroid
Mechanism of action Corticosteroid Hormone Receptor Agonists
DEA schedule Non-controlled
Marketing category ANDA
Marketing status Discontinued
FDA listing status Discontinued by firm (certified through Oct 2015)
Marketing start 2015-04-14
Route TOPICAL
Dosage form CREAM
Substance TRIAMCINOLONE ACETONIDE
TE code (Orange Book) AT · RLD · RS

Drug-database identifiers Medi-Span GPI and First Databank GCN / HICL / AHFS classification

GPI-14 90550085103705
GPI class Triamcinolone Acetonide
GCN Seq No 007593
GCN 31231
HICL code 002891
Ingredient (HICL) Triamcinolone Acetonide
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5P
Therapeutic class — specific (HIC3) Topical Anti-Inflammatory Steroidal
AHFS code 48:10.08.00
AHFS class Corticosteroids (Respiratory Tract)
FDB label name TRIAMCINOLONE 0.025% CREAM
FDB brand name Triamcinolone Acetonide
Legend status F — Federal legend — prescription drug or device
Quick answers
  • GSN (GCN sequence number): 007593
  • GCN: 31231
  • GPI-14 (Medi-Span): 90550085103705
  • HICL (First Databank): 002891
  • AHFS class code: 48:10.08.00
  • RxCUI (RxNorm): 1014314
Why two NDCs? The FDA registers this code as 0713-0226-15 — a 4-4-2 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the labeler segment → 00713-0226-15. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

RxNorm drug class

This medicine belongs to the Corticosteroid class.

Pharmacologic class Corticosteroid
Drug family (ATC) Corticosteroids for local oral treatment, Corticosteroids, Corticosteroids, moderately potent (group II)
How it works Corticosteroid Hormone Receptor Agonists
Where does this data come from?
Therapeutic classes from RxNorm RxClass (U.S. National Library of Medicine) — Established Pharmacologic Class (FDA), ATC drug family (WHO) and mechanism of action, matched by this product’s RxCUI.

Clinical

Label name TRIAMCINOLONE 0.025% CREAM Ingredient Triamcinolone Acetonide
📖 What it is MedlinePlus · NLM

Triamcinolone topical is used to treat the itching, redness, dryness, crusting, scaling, inflammation, and discomfort of various skin conditions, including psoriasis (a skin disease in which red, scaly patches form on some areas of the body and eczema (a skin disease that causes the skin to be dry and itchy and to sometimes develop red, scaly rashes). It is also used as a dental paste to relieve the discomfort of mouth sores. Triamcinolone is in a class of medications called corticosteroids. It works by activating natural substances in the skin to reduce swelling, redness, and itching.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • It depends on the product. Injections treat severe allergic conditions, joint inflammation, certain skin problems and eye inflammation. Creams and ointments calm itchy, inflamed sk...
  • Injections are given by a healthcare professional. Ointment is applied as a thin film to the affected area two to three times daily. Nasal spray bottles need priming before first u...
  • Possible effects include injection site pain, joint swelling, headache, muscle spasms, cough, sinusitis and bruising. People with diabetes may see higher blood sugar. Tell your doc...
  • Call right away for signs of an allergic reaction, fever or infection, a very painful and swollen joint, vision changes, or mood changes. Also report black stools, severe stomach p...
📖 Read our full Triamcinolone guide →
8
Nutrient depletion considerations

Triamcinolone Acetonide may be associated with lower levels of 8 nutrients — worth a chat with your pharmacist, not a cause for alarm.

🧪 Full Triamcinolone Acetonide nutrient depletion report →
An association is not a deficiency. Educational only — don't start or stop anything without professional guidance.
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer gPer package
Retail pharmacies payNADAC · weekly $0.120 $1.80 / 15 g
Medicaid paysCMS SDUD · 12 mo $0.3580 $5.37 / 15 g
Medicare drug plans payPart D · Q2 2026 $0.1230 $1.85 / 15 g
NADAC price history (per g) — tap or hover for the price & month
Jan 2022 Aug 2022 Jan 2026 Sep 2026 $0.170 $0.115
▼ Down 24% over the last 24 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

Packaging — all sizes for this product

Package NDCDescription Per unit Per pack Marketing startMarketing endStatus
00713-0226-15 You're viewing this Main listing 1 TUBE in 1 CARTON / 15 g in 1 TUBE $0.1198 / g $1.80 2015-04-14 — Discontinued by firm
00713-0226-80 0713-0226-80 1 TUBE in 1 CARTON / 80 g in 1 TUBE $0.0532 / g $4.26 2015-04-14 — Discontinued by firm

Per g, this pack runs about 125% above the cheapest pack (NDC 00713-0226-80, $0.0532 vs $0.1198 NADAC).

In Medicaid, this is the most-dispensed pack of this product — about 65% of fills over the last four reported quarters. See all packs ↓

Pack size FAQ

What quantity is in this package?
This package is listed by the FDA — 1 tube in 1 carton / 15 g in 1 tube.
What NDC number is used to bill for this package of Triamcinolone Acetonide .25 mg/g Cream?
Use the 11-digit billing form listed in the identifiers section of this page. Pharmacy and medical claims use the 11-digit form; the FDA label may print a shorter form of the same code.

Prices are the latest CMS NADAC pharmacy acquisition cost per NDC; per-pack figures are per-unit × pack quantity, shown only when the pack is denominated in the same measure NADAC prices.

Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Triamcinolone Acetonide .25 mg/g 45802-0063-05 Padagis 454 g $0.035 AT Availability likely save 71%
Triamcinolone Acetonide .25 mg/g 45802-0054-05 Padagis 454 g $0.047 AT Availability likely save 61%
Triamcinolone Acetonide .25 mg/g 00168-0005-80 E. 80 g $0.074 AT Availability likely save 38%
triamcinolone acetonide .25 mg/g 00168-0003-15 E. 1 tube $0.120 AT Availability likely —
Triamcinolone Acetonide .25 mg/gthis 00713-0226-15 Cosette 1 tube $0.120 AT Discontinued —
Triamcinolone Acetonide .25 mg/g 16714-0985-01 NorthStar 1 tube $0.120 AT Availability likely —
Triamcinolone Acetonide .25 mg/g 33342-0327-15 Macleods 1 tube $0.120 AT Availability likely —
Triamcinolone Acetonide .25 mg/g 67877-0317-15 Ascend 15 g $0.120 AT Availability likely —
Triamcinolone acetonide .25 mg/g 33342-0331-15 Macleods 1 tube $0.239 AT Availability likely +100%
Triamcinolone Acetonide .25 mg/g 00713-0229-15 Cosette 1 tube $0.239 AT Availability likely +100%
Triamcinolone acetonide .25 mg/g 16714-0267-01 NorthStar 1 tube $0.239 AT Availability likely +100%
Triderm .25 mg/g 00316-0165-15 Crown 1 tube — AT FDA listed —
triamcinolone acetonide .25 mg/g 50090-0293-01 A-S 1 tube — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 50090-2658-00 A-S 15 g — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 50090-3704-00 A-S 1 tube — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 63187-0214-80 Proficient 80 g — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 63629-8782-01 Bryant 15 g — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 63629-8784-01 Bryant 454 g — AT FDA listed —
Triamcinolone acetonide .25 mg/g 68071-2361-01 NuCare 15 g — AT FDA listed —
triamcinolone acetonide .25 mg/g 68788-8515-08 Preferred 1 tube — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 68788-8899-01 Preferred 15 g — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 71335-2870-01 Bryant 454 g — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 72162-1835-02 Bryant 454 g — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 72162-2334-02 Bryant 1 tube — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 76420-0347-15 Asclemed 1 tube — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 76420-0360-80 Asclemed 80 g — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 63629-8841-01 Bryant 80 g — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 72162-2335-02 Bryant 1 tube — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 50090-3802-00 A-S 1 tube — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 68788-4148-01 Preferred 1 tube — AT FDA listed —
Triamcinolone Acetonide .25 mg/g 50090-0362-00 A-S 1 tube — AT FDA listed —
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2015
On the market since
Apr 2015
📍
2026
Currently FDA-listed
11 years listed
🔓
·
Generic on the market
this product is a generic
✅This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

What it looks like

Color white
One label can cover several strengths, so colors may be combined — always confirm a loose pill against the dispensed prescription label or a pharmacist.
Where does this data come from?
Physical description (imprint, shape, color, scoring, coating) from this product’s FDA Structured Product Labeling (SPL), mirrored from DailyMed / openFDA.

Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII 936JST6JCN
    Cetyl alcohol is a waxy, fatty substance derived from plant or animal sources. It acts as an emulsifier and thickener in medicines, helping blend oil and water components and giving products a smooth, creamy texture.
  • UNII 8CRQ2TH63M
    Isopropyl palmitate is an oily liquid derived from palm oil. It acts as an emollient and lubricant in medicines, helping soften the skin or improve how the product spreads and flows.
  • UNII 884C3FA9HE
    Lanolin alcohol is a waxy substance derived from sheep's wool. It functions as an emollient and emulsifier in medicines, helping blend oil and water-based ingredients while softening the product's texture.
  • UNII A2I8C7HI9T
    Methylparaben is a preservative derived from benzoic acid that prevents growth of bacteria, fungi, and mold in medicines. It extends the product's shelf life and maintains safety during storage.
  • UNII T5L8T28FGP
    Mineral oil is a clear, odorless liquid derived from crude oil. It acts as a lubricant and emollient in medications, helping pills slide smoothly during manufacturing and aiding moisture retention in topical products.
  • UNII 13A4J4NH9I
    A synthetic emulsifier derived from stearic acid and polyethylene glycol. It helps mix oil and water-based ingredients together in liquid medicines and creams to create a smooth, uniform product.
  • UNII CAL22UVI4M
    A synthetic emulsifier derived from sorbitol and fatty acids. It helps mix oil and water-based ingredients together and improves the texture and stability of the medicine.
  • UNII 6DC9Q167V3
    Propylene glycol is a clear liquid derived from petroleum or vegetable sources. It acts as a solvent, humectant, and preservative in medicines, helping dissolve active ingredients and maintain product stability.
  • UNII MZM1I680W0
    Propylene glycol stearate is a waxy substance made by combining stearic acid with propylene glycol. It acts as an emulsifier to help blend oil and water ingredients, and also serves as a thickener or stabilizer in the medicine.
  • UNII Z8IX2SC1OH
    Propylparaben is a chemical preservative used to prevent bacterial and fungal growth in medicines and personal care products. It helps extend shelf life and maintain product safety during storage.
  • UNII X045WJ989B
    Sorbic acid is a preservative derived from berries that prevents mold, yeast, and bacterial growth in medicines. It keeps the product stable and safe during storage.
  • UNII NVZ4I0H58X
    A waxy substance made from sorbitol and stearic acid. It acts as an emulsifier and stabilizer, helping keep oil and water mixed together and preventing separation in the medicine.
  • UNII 059QF0KO0R
    Water is a liquid solvent that dissolves and mixes ingredients together in liquid medicines, syrups, and injections. It helps distribute the active drug evenly throughout the product.

13 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMed — ingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

Manufacturer & labeler

LabelerCosette Pharmaceuticals, Inc.
Application holderCOSETTE PHARMACEUTICALS NC LABORATORIES LLC
FDA applicationANDA089797 (ANDA)
Labeler code00713
First marketedApr 2015
Product typeHuman Prescription Drug
Portfolio99 products on file

More NDCs from Cosette Pharmaceuticals, Inc. labeler code 00713

The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage ⏱️ Dosage and Administration ⛔ Contraindications 🤒 Adverse Reactions 🤰 Pregnancy 🧒 Pediatric Use 🆘 Overdosage 🧬 Clinical Pharmacology 📦 How Supplied / Storage and Handling 📦 Storage and Handling 📋 Description 💬 Information for Patients ⚠️ Precautions 🍼 Nursing Mothers 🧬 Pharmacokinetics 📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 📄 Package Label / Principal Display Panel
🎯 Indications and Usage 19 words ▾

INDICATIONS AND USAGE Topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses.

⏱️ Dosage and Administration 71 words ▾

DOSAGE AND ADMINISTRATION Apply Triamcinolone Acetonide Cream USP 0.025% to the affected area two to four times daily. Rub in gently. Apply the 0.1% Triamcinolone Acetonide Cream, as appropriate, to the affected area two to three times daily.

Rub in gently. Occlusive dressings may be used for the management of psoriasis or recalcitrant conditions. If an infection develops, the use of occlusive dressings should be discontinued and appropriate antimicrobial therapy instituted.

⛔ Contraindications 21 words ▾

CONTRAINDICATIONS Topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

🤒 Adverse Reactions 79 words ▾

ADVERSE REACTIONS The following local adverse reactions are reported infrequently with topical corticosteroids, but may occur more frequently with the use of occlusive dressings. These reactions are listed in an approximate decreasing order of occurrence: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. To report SUSPECTED ADVERSE REACTIONS, contact Cosette Pharmaceuticals, Inc. at 1-800-922-1038 or FDA at 1-800-FDA-1088 or www.fda.gov /medwatch .

🤰 Pregnancy 96 words ▾

Pregnancy: Teratogenic Effects - Pregnancy Category C Corticosteroids are generally teratogenic in laboratory animals when administered systemically at relatively low dosage levels. The more potent corticosteroids have been shown to be teratogenic after dermal application in laboratory animals. There are no adequate and well-controlled studies in pregnant women on teratogenic effects from topically applied corticosteroids.

Therefore, topical corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Drugs of this class should not be used extensively on pregnant patients, in large amounts, or for prolonged periods of time.

🧒 Pediatric Use 114 words ▾

Pediatric Use Pediatric patients may demonstrate greater susceptibility to topical corticosteroid-induced HPA axis suppression and Cushing's syndrome than mature patients because of a larger skin surface area to body weight ratio. Hypothalamic-pituitary-adrenal (HPA) axis suppression, Cushing's syndrome, and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include linear growth retardation, delayed weight gain, low plasma cortisol levels, and absence of response to ACTH stimulation.

Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema. Administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. Chronic corticosteroid therapy may interfere with the growth and development of children.

🆘 Overdosage 17 words ▾

OVERDOSAGE Topically applied corticosteroids can be absorbed in sufficient amounts to produce systemic effects (See PRECAUTIONS ).

🧬 Clinical Pharmacology 60 words ▾

CLINICAL PHARMACOLOGY Topical corticosteroids share anti-inflammatory, anti-pruritic and vasoconstrictive actions. The mechanism of anti-inflammatory activity of the topical corticosteroids is unclear. Various laboratory methods, including vasoconstrictor assays, are used to compare and predict potencies and/or clinical efficacies of the topical corticosteroids.

There is some evidence to suggest that a recognizable correlation exists between vasoconstrictor potency and therapeutic efficacy in man.

📦 How Supplied / Storage and Handling 37 words ▾

HOW SUPPLIED Triamcinolone Acetonide Cream USP 0.025% 15 gram tubes NDC 0713-0226-15 80 gram tubes NDC 0713-0226-80 Triamcinolone Acetonide Cream USP 0.1% 15 gram tubes NDC 0713-0225-15 30 gram tubes NDC 0713-0225-31 80 gram tubes NDC 0713-0225-80

📦 Storage and Handling 37 words ▾

STORAGE Store at 20-25°C (68-77°F) [ see USP Controlled Room Temperature ]. Keep out of reach of children. Avoid excessive heat. Protect from freezing. Distributed by: Cosette Pharmaceuticals, Inc. South Plainfield, NJ 07080 Rev. 03/2022 8-TRIACRCPLNC2 VC7611

📋 Description 161 words ▾

FOR EXTERNAL USE ONLY NOT FOR OPHTHALMIC USE Rx Only DESCRIPTION Triamcinolone Acetonide Cream USP contains triamcinolone acetonide [Pregna-1,4-diene-3,20-dione, 9-fluoro-11,21-dihydroxy-16,17-[(1-methylethylidene)bis- (oxy)]-, (11β,16α)-], with the empirical formula C 24 H 31 FO 6 and molecular weight 434.50. CAS 76-25-5. Triamcinolone Acetonide Cream USP 0.025% contains: 0.25 mg of triamcinolone acetonide USP per gram in a water washable cream base consisting of mineral oil (and) lanolin alcohol, isopropyl palmitate NF, propylene glycol stearate, propylene glycol USP, cetyl alcohol NF, sorbitan monostearate NF, polysorbate 60 NF, sorbic acid NF, polyoxyl (40) stearate NF, propylparaben NF, methylparaben NF and purified water USP.

Triamcinolone Acetonide Cream USP 0.1% contains: 1 mg of triamcinolone acetonide USP per gram in a water washable cream base consisting of mineral oil (and) lanolin alcohol, isopropyl palmitate NF, propylene glycol stearate, propylene glycol USP, cetyl alcohol NF, sorbitan monostearate NF, polysorbate 60 NF, sorbic acid NF, polyoxyl (40) stearate NF, propylparaben NF, methylparaben NF and purified water USP. Triamcinolone Acetonide Cream-1

💬 Information for Patients 128 words ▾

Information for the Patient Patients using topical corticosteroids should receive the following information and instructions. 1. This medication is to be used as directed by the physician.

It is for external use only. Avoid contact with the eyes. 2.

Patients should be advised not to use this medication for any disorder other than for which it was prescribed. 3. The treated skin area should not be bandaged or otherwise covered or wrapped as to be occlusive unless directed by the physician.

4. Patients should report any signs of local adverse reactions especially under occlusive dressing. 5.

Parents of pediatric patients should be advised not to use tight fitting diapers or plastic pants on a child being treated in the diaper area, as these garments may constitute occlusive dressings.

⚠️ Precautions 219 words ▾

PRECAUTIONS General Systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (HPA) axis suppression, manifestations of Cushing's syndrome, hyperglycemia, and glucosuria in some patients. Conditions which augment systemic absorption include the application of the more potent steroids, use over large surface areas, prolonged use, and the addition of occlusive dressings. Therefore, patients receiving a large dose of a potent topical steroid applied to a large surface area or under an occlusive dressing should be evaluated periodically for evidence of HPA axis suppression by using the urinary free cortisol and ACTH stimulation tests.

If HPA axis suppression is noted, an attempt should be made to withdraw the drug, to reduce the frequency of application, or to substitute a less potent steroid. Recovery of HPA axis function is generally prompt and complete upon discontinuation of the drug. Infrequently, signs and symptoms of steroid withdrawal may occur, requiring supplemental systemic corticosteroids.

Children may absorb proportionally larger amounts of topical corticosteroids and thus be more susceptible to systemic toxicity (See PRECAUTIONS-Pediatric Use ). If irritation develops, topical corticosteroids should be discontinued and appropriate therapy instituted. In the presence of dermatological infections, the use of an appropriate anti-fungal or antibacterial agent should be instituted.

If a favorable response does not occur promptly, the corticosteroid should be discontinued until the infection has been adequately controlled.

🍼 Nursing Mothers 58 words ▾

Nursing Mothers It is not known whether topical administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids are secreted into breast milk in quantities not likely to have a deleterious effect on the infant. Nevertheless, caution should be exercised when topical corticosteroids are administered to a nursing woman.

🧬 Pharmacokinetics 132 words ▾

Pharmacokinetics The extent of percutaneous absorption of topical corticosteroids is determined by many factors including the vehicle, the integrity of the epidermal barrier, and the use of occlusive dressings. Topical corticosteroids can be absorbed from normal intact skin. Inflammation and/or other disease processes in the skin increase percutaneous absorption.

Occlusive dressings substantially increase the percutaneous absorption of topical corticosteroids. Thus, occlusive dressings may be a valuable therapeutic adjunct for treatment of resistant dermatoses (See DOSAGE AND ADMINISTRATION ). Once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids.

Corticosteroids are bound to plasma proteins in varying degrees. Corticosteroids are metabolized primarily in the liver and are then excreted by the kidneys. Some of the topical corticosteroids and their metabolites are also excreted into the bile.

📄 Carcinogenesis, Mutagenesis, Impairment of Fertility 38 words ▾

Carcinogenesis, Mutagenesis, and Impairment of Fertility Long-term animal studies have not been performed to evaluate the carcinogenic potential or the effect on fertility of topical corticosteroids. Studies to determine mutagenicity with prednisolone and hydrocortisone have revealed negative results.

📄 Package Label / Principal Display Panel 143 words ▾

PRINCIPAL DISPLAY PANEL NDC 0713-0225-15 Triamcinolone Acetonide Cream, USP 0.1% 15 g Rx only FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE. Cosette Pharmaceuticals, Inc.

NDC 0713-0225-31 Triamcinolone Acetonide Cream, USP 0.1% 30 g Rx only FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE. Cosette Pharmaceuticals, Inc.

NDC 0713-0225-80 Triamcinolone Acetonide Cream, USP 0.1% 80 g Rx only FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE. Cosette Pharmaceuticals, Inc.

NDC 0713-0226-15 Triamcinolone Acetonide Cream, USP 0.1% 15 g Rx only FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE. Cosette Pharmaceuticals, Inc.

NDC 0713-0226-80 Triamcinolone Acetonide Cream, USP 0.1% 80 g Rx only FOR EXTERNAL USE ONLY. NOT FOR OPHTHALMIC USE. Cosette Pharmaceuticals, Inc.

Triamcinolone Acetonide Cream-2 Triamcinolone Acetonide Cream-3 Triamcinolone Acetonide Cream-4 Triamcinolone Acetonide Cream-5 Triamcinolone Acetonide Cream-6 Triamcinolone Acetonide Cream-7 Triamcinolone Acetonide Cream-8 Triamcinolone Acetonide Cream-9 Triamcinolone Acetonide Cream-10 Triamcinolone Acetonide Cream-11

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗

Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for this package alone, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q1 2026 · 5 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
22.7K
Units reimbursed last 4 qtrs
576.6K
Gross reimbursed last 4 qtrs
$206.4K
Avg / prescription
$9.09
Avg / unit
$0.3580
Latest quarter Q1 2026
4.4KRx
Medicaid pays / g
$0.3580
gross reimbursed
vs
NADAC / g
$0.1198
acquisition cost
=
Spread
+$0.2382
+199% vs cost
What Medicaid paid per g (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care ⓘ
39% FFS 61% MCO
Fee-for-service · 8,781 Rx Managed care · 13,926 Rx
State Medicaid map
Alaska: no data reported AK Maine: 540 units · 38.7 per 100k residents ME Washington: 9,900 units · 127 per 100k residents WA Idaho: 1,965 units · 100 per 100k residents ID Montana: 225 units · 19.9 per 100k residents MT North Dakota: no data reported ND Minnesota: 7,380 units · 129 per 100k residents MN Wisconsin: 13,395 units · 227 per 100k residents WI Michigan: 27,405 units · 273 per 100k residents MI New York: 14,805 units · 75.6 per 100k residents NY Vermont: no data reported VT New Hampshire: no data reported NH Oregon: 3,795 units · 89.7 per 100k residents OR Nevada: 8,340 units · 261 per 100k residents NV Wyoming: no data reported WY South Dakota: no data reported SD Iowa: 6,615 units · 206 per 100k residents IA Illinois: 39,390 units · 314 per 100k residents IL Indiana: 8,475 units · 124 per 100k residents IN Ohio: 15,525 units · 132 per 100k residents OH Pennsylvania: 18,480 units · 143 per 100k residents PA New Jersey: 16,595 units · 179 per 100k residents NJ Massachusetts: 10,380 units · 148 per 100k residents MA California: 108,445 units · 278 per 100k residents CA Utah: no data reported UT Colorado: 5,610 units · 95.4 per 100k residents CO Nebraska: 4,545 units · 230 per 100k residents NE Missouri: 10,110 units · 163 per 100k residents MO Kentucky: 5,355 units · 118 per 100k residents KY West Virginia: 1,605 units · 90.7 per 100k residents WV Virginia: 6,705 units · 76.9 per 100k residents VA Maryland: 9,770 units · 158 per 100k residents MD Connecticut: 8,025 units · 222 per 100k residents CT Rhode Island: 3,390 units · 310 per 100k residents RI Arizona: 3,315 units · 44.6 per 100k residents AZ New Mexico: 11,910 units · 563 per 100k residents NM Kansas: 3,510 units · 119 per 100k residents KS Arkansas: 4,290 units · 140 per 100k residents AR Tennessee: 54,620 units · 766 per 100k residents TN North Carolina: 36,870 units · 340 per 100k residents NC South Carolina: 4,350 units · 81.0 per 100k residents SC Delaware: 6,300 units · 611 per 100k residents DE Oklahoma: 11,385 units · 281 per 100k residents OK Louisiana: 39,525 units · 864 per 100k residents LA Mississippi: 3,435 units · 117 per 100k residents MS Alabama: 405 units · 7.9 per 100k residents AL Georgia: no data reported GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 22,695 units · 74.4 per 100k residents TX Florida: 7,230 units · 32.0 per 100k residents FL
Units reimbursed · per 100k residents
7.9864
gray = no data reported ⓘ
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Louisiana 864 /100k
2 Tennessee 766 /100k
3 Delaware 611 /100k
4 New Mexico 563 /100k
5 North Carolina 340 /100k
6 Illinois 314 /100k
7 Rhode Island 310 /100k
8 Oklahoma 281 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

Medicaid utilization by pack size

Medicaid (SDUD) totals over the four most recent reported quarters for every package size of this drug — handy when a specific package (e.g. a starter/titration pack) carries little or no Medicaid volume on its own.
1 tube this page00713-0226-15 22,707 Rx · $206,407
1 tube00713-0226-80 12,286 Rx · $127,038
Drug total (last 4 qtrs): 34,993 Rx · 1,561,980 units · $333,445 gross reimbursed
Tap a pack size to open its page. Source: CMS State Drug Utilization Data, last 4 quarters.

Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Triamcinolone Acetonide — the program that covers self-administered drugs. 22 manufacturers.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Triamcinolone Acetonide. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$17.79M
Claims incl. refills
1.7M
Beneficiaries
1.4M
Spend / beneficiary
$13.01
Spend / claim
$10.45
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

About this NDC listing & data coverage

Finished prescription product No longer marketed (per FDA listing data)
What data is (and isn’t) available for this NDC — tap to expand
NDC identity (package / product / labeler codes) ✓ Available
Labeler ✓ Available
Product & package description ✓ Available
Marketing category & status ✓ Available
Active ingredient / dosage form / route ✓ Available
FDA label (SPL via DailyMed) ✓ Available
Package photos ✓ Available
Inactive ingredients (structured) ✓ Available
NADAC pharmacy acquisition price (CMS) ✓ Available
Orange Book / therapeutic-equivalence data ✓ Available
HCPCS J-code billing crosswalk — Not published for this NDC Most self-administered / retail products have no J-code — that is normal.
Medicaid utilization (CMS SDUD) ✓ Available
“Not published” reflects what the public FDA / CMS / NLM sources provide for this exact package code — it is a property of the data feeds, not a judgment about the product.

Questions about this listing

What does the discontinued status mean for this NDC?
The labeler reported a marketing end date (or the listing was delisted), so this specific package is no longer actively marketed. Remaining stock may still be dispensed for a time, and the NDC stays valid for historical records and claims — but data feeds (pricing, labeling) typically stop updating for it. Other package sizes or other manufacturers' versions of the same medication may still be marketed — see the equivalents section where available.
Is the NDC printed on the package the same as the 11-digit billing NDC?
Yes, they identify this exact package in different formats. The form printed on the packaging and shown on DailyMed is the one the FDA registered. Insurance claims use a fixed 11-digit 5-4-2 format, so the short segment is padded with a leading zero and the dashes are dropped. The Identity section at the top of this page lists each form of this code.
Does this product come in other package sizes?
Yes — the FDA directory lists 1 other package presentation of this same product, including 1 tube (00713-0226-80). Each has its own NDC and its own page — see the package list near the top of this page.
Who lists this product with the FDA?
Cosette Pharmaceuticals, Inc. is the labeler of record for this NDC — the company under whose FDA-assigned code the package is listed. The labeler may be the manufacturer itself or a distributor marketing the product under its own code.
Do I need a prescription for this product?
This NDC is listed with FDA as a prescription product, so it is dispensed under a prescriber's order. Your pharmacist can tell you whether any over-the-counter forms of the same medication exist.
This page identifies an FDA-listed package (the NDC) and reports public regulatory and pricing data about the listing. It is reference information, not a medical recommendation — talk to your pharmacist or prescriber about your own medication.
Where does this data come from?
Listing facts (marketing category, packager status, marketing dates) from the FDA openFDA NDC Directory; label availability from DailyMed; pricing coverage from CMS NADAC; equivalence scope from the FDA Orange Book.
← 00713-0225-15 · Cosette 00713-0228-15 · Cosette →
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.